These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3429788)

  • 1. Effect of verapamil on aldosterone secretion in primary aldosteronism.
    Opocher G; Rocco S; Murgia A; Mantero F
    J Endocrinol Invest; 1987 Oct; 10(5):491-4. PubMed ID: 3429788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of naloxone on the adrenal cortex in primary aldosteronism.
    Fallo F; Boscaro M; Sonino N; Mantero F
    Am J Hypertens; 1988 Jul; 1(3 Pt 1):280-2. PubMed ID: 2839206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism.
    Mantero F; Fallo F; Opocher G; Armanini D; Boscaro M; Scaroni C
    Clin Sci (Lond); 1981 Dec; 61 Suppl 7():289s-293s. PubMed ID: 7032817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.
    Giacchetti G; Ronconi V; Turchi F; Agostinelli L; Mantero F; Rilli S; Boscaro M
    J Hypertens; 2007 Jan; 25(1):177-86. PubMed ID: 17143190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of aldosterone secretion in primary aldosteronism.
    Spark RF; Dale SL; Kahn PC; Melby JC
    J Clin Invest; 1969 Jan; 48(1):96-104. PubMed ID: 4303791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma.
    Rossitto G; Regolisti G; Rossi E; Negro A; Nicoli D; Casali B; Toniato A; Caroccia B; Seccia TM; Walther T; Rossi GP
    Hypertension; 2013 Feb; 61(2):526-33. PubMed ID: 23248149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism.
    Wisgerhof M; Brown RD; Hogan MJ; Carpenter PC; Edis AJ
    J Clin Endocrinol Metab; 1981 Feb; 52(2):195-8. PubMed ID: 7462385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of captopril on aldosterone response to potassium infusion in primary aldosteronism.
    Fallo F; Chouman M; Pagotto U; Pistorello M
    Miner Electrolyte Metab; 1991; 17(3):185-9. PubMed ID: 1779941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nocturnal, daytime, and postural changes of plasma aldosterone before and during dexamethasone in adenomatous and idiopathic aldosteronism.
    Hoefnagels WH; Drayer JI; Smals AG; Benraad TJ; Kloppenborg PW
    J Clin Endocrinol Metab; 1980 Dec; 51(6):1330-4. PubMed ID: 7440698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of [des-aspartyl1]-angiotensin II in primary aldosteronism.
    Carey RM; Ayers CR; Vaughan ED; Peach MJ; Herf SM
    J Clin Invest; 1979 Apr; 63(4):718-26. PubMed ID: 438332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and chronic effect of nifedipine in primary aldosteronism.
    Carpenè G; Rocco S; Opocher G; Mantero F
    Clin Exp Hypertens A; 1989; 11(7):1263-72. PubMed ID: 2805362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma.
    Rossi GP; Belfiore A; Bernini G; Desideri G; Fabris B; Ferri C; Giacchetti G; Letizia C; Maccario M; Mallamaci F; Mannelli M; Montemurro D; Palumbo G; Rizzoni D; Rossi E; Semplicini A; Agabiti-Rosei E; Pessina AC; Mantero F;
    J Hypertens; 2007 Jul; 25(7):1433-42. PubMed ID: 17563566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism.
    Matsumoto T; Oki K; Kajikawa M; Nakashima A; Maruhashi T; Iwamoto Y; Iwamoto A; Oda N; Hidaka T; Kihara Y; Kohno N; Chayama K; Goto C; Aibara Y; Noma K; Liao JK; Higashi Y
    Hypertension; 2015 Apr; 65(4):841-8. PubMed ID: 25624340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension].
    Song AL; Zeng ZP; Tong AL; Lu L; Chen S; Li M; Fu CL; Wang YH; Sun ML
    Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):294-8. PubMed ID: 22781950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism.
    Prejbisz A; Postuła M; Cybulska I; Dobrucki T; Kabat M; Peczkowska M; Janas J; Janaszek-Sitkowska H; Makowiecka-Cieśla M; Januszkiewicz A
    Kardiol Pol; 2003 Jan; 58(1):17-26. PubMed ID: 14502298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic regulation of aldosterone secretion: assessment in different subtypes of primary aldosteronism and in essential hypertension.
    Veglio F; Pinna G; Rabbia F; Panarelli M; Bisbocci D; Melchio R; Chiandussi L
    J Int Med Res; 1991; 19(1):44-9. PubMed ID: 1850365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of verapamil on the aldosterone-stimulating properties of metoclopramide: in vitro and in vivo studies.
    Opocher G; Murgia A; Rocco S; D'Agostino D; Boscaro M; Menegus A; Mantero F
    Horm Metab Res; 1986 Nov; 18(11):775-8. PubMed ID: 3792997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dispensable role for P450(scc) in the overproduction of aldosterone in aldosterone-producing adenoma and idiopathic hyperaldosteronism in patients with primary aldosteronism.
    Fang Y; Zhao L; Zang M; Chen S; Yan F; Di X; Duren A
    Pathol Oncol Res; 2010 Dec; 16(4):589-92. PubMed ID: 20066577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism.
    Somlóová Z; Widimský J; Rosa J; Wichterle D; Strauch B; Petrák O; Zelinka T; Vlková J; Masek M; Dvoráková J; Holaj R
    J Hum Hypertens; 2010 Oct; 24(10):625-30. PubMed ID: 20574447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism.
    Ohno Y; Sone M; Inagaki N; Yamasaki T; Ogawa O; Takeda Y; Kurihara I; Umakoshi H; Ichijo T; Katabami T; Wada N; Ogawa Y; Yoshimoto T; Kawashima J; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Miyauchi S; Kamemura K; Fukuoka T; Yamamoto K; Otsuki M; Suzuki T; Naruse M;
    J Clin Endocrinol Metab; 2018 Dec; 103(12):4456-4464. PubMed ID: 30165444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.